Abstract
Reduced-antigen-content pertussis vaccines designed initially for booster vaccination of adolescents and adults can also be used to vaccinate pre-school age children. Combination vaccines, which reduce the number of administered injections, combine multiple antigens including inactivated poliovirus (IPV), which is recommended in this age group in some countries. This randomised, controlled study compared a combined diphtheria-tetanus-acellular pertussis-inactivated polio-containing booster vaccine, dTpa-IPV (Boostrix™ Polio, n = 822), to separately administered dTpa (Boostrix™) and IPV (IPV Mérieux™, n = 136) in 4–8-year-old children who had previously received four doses of DTPa. Additional serological assessment was performed 1 year after the booster dose. One month after vaccination, seroprotection/vaccine response rates were similar for both groups. At least 99.9% of the subjects had protective antibodies against diphtheria, tetanus and polio, and at least 90.1% had a vaccine response to pertussis antigens after dTpa-IPV. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV. Fever and grade 3 loss of appetite occurred more commonly after dTpa-IPV, whereas swelling and grade 3 pain occurred more frequently after separately administered dTpa + IPV (P < 0.05 for all). However, 95% CIs overlapped in all cases. Large swelling reactions after dTpa-IPV occurred less commonly than have been reported after a fifth dose of DTPa. One year after the booster, 98.6% of the subjects tested continued to have protective antibodies against diphtheria, tetanus and polio, and at least 81.2% were seropositive for pertussis components. The reduced-antigen-content dTpa-IPV vaccine was immunogenic, well tolerated and safe in pre-school age children. It provides immunity against four diseases in a single injection, with the potential reactogenicity benefit of a reduced-antigen dose.
Similar content being viewed by others
Abbreviations
- ATP:
-
according to protocol
- DTPa:
-
diphtheria, tetanus and acellular pertussis vaccine
- DTPw:
-
diphtheria, tetanus and whole-cell pertussis vaccine
- dTpa:
-
reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine
- IPV:
-
inactivated polio virus
- CI:
-
confidence interval
- GMC/T:
-
geometric mean concentration/titre
- OPV:
-
oral polio vaccine
- PT:
-
pertussis toxin
- FHA:
-
filamentous haemagglutinin
- PRN:
-
pertactin
- SAE:
-
serious adverse event
References
The Australian Immunisation Handbook, 8th edn (2003) National Health & Medical Research Council
Bulletin Epidémiologique Hebdomadaire. Calendrier vaccinal (2003) Avis du Conseil supérieur d’hygiène publique de France 06:33–37
Canadian Immunization Guide 6th edition (2002) Population and Public Health Branch, Centre for Infectious Disease Prevention and Control
Centers for Disease Control and Prevention (2000) Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations if the Advisory Committee on Immunization Practices (ACIP). MMWR 49 (RR-13):1–8
Cherry JD, Olin P (1999) The science and fiction of pertussis vaccines. Pediatrics 104:1381–1384
Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter M, Schuerman L (2004) Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 23:336–342
Collins CL, Salt P, McCathy N, Chantler T, Lane L, Hemme F, Diggle L, Buttery J, Kitchin NRE, Moxon ER, Pollard AJ (2004) Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22:4262–4269
Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut (2003) Epidemiologisches Bull 32:245–260
Granstrom M, Granstrom G (1993) Serological correlates in whooping cough. Vaccine 11:445–448
Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter JM, Schuerman LM (2005) Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 23:3657–3667
Gustafsson L, Hallander HO, Olin P (2005) Seven year report. Pertussis surveillance in Sweden. Progress Report October 1997-September 2004. Avdelningen För Immunologi Och Vaccinologi Smittskyddsinstitutet
He Q, Viljanen MK, Nikkari S, Lyytikainen R, Mertsola J (1994) Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 170:873–877
Isacson J, Trollfors B, Taranger J, Zackrisson G, Lagergard T (1993) How common is whooping cough in a nonvaccinating country? Pediatr Infect Dis J 12:284–288
Pichichero M, Deloria M, Rennels M, Anderson E, Edwards K, Decker M, Englund J, Steinhoff M, Deforest A, Meade B (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 100:772–788
Rennels MB (2003) Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Ped Infect Dis 14:196–198
Scheifle DW, Halperin SA, Ferguson AC (2001) Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin test with vaccine antigens. Vaccine 19:4720–4726
Skowronski DM, Remple VP, Macnabb J, Pielak K, Patrick DM, Halperin SA, Scheifele D (2003) Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 112:e453–e459
Storsaeter J, Hallander HO, Gustafsson L, Olin P (2003) Low levels of anti pertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 21:3542–3549
Torvaldsen S, McIntyre PB (2003) Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 22:956–959
Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Atti ML, Mastrantonio P, Giammanco A, Progetto Pertosse Study Group (2001) Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 107:e25
Vergara R, Tregnaghi M, Ussher J, Navarro S, Rüttimann R, Potin M, Wolter J, Schuerman L (2005) Reduced-antigen dTpa-IPV vaccine as a booster for adolescents 10 to 14 years of age. Eur J Ped 164:377–382
Woo EJ, Burwen DR, Gatumu SNM, Ball R, the Vaccine Adverse Event Reporting System (VAERS) Working Group (2003) Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis 37:351–358
World Health Organisation standard procedure for determining immunity to poliovirus using the microneutralization test (WHO/EPI/Gen 93.9)
Acknowledgements
Participating investigators: Drs J. Banz, U. Behre, K. Bennett, F. Bertholdt, H. Berwanger, H. Bolze-Knothe, H-M. Burow, M. Collet, J. Disselhoff, Z. Dogrul, F-P. Drobnitzky, R. Erdl, R. Freund, F. Gamerdinger, W. Geltinger, PK. Gildberg, H. Glaser, D. Goepel-Abtt, S. Habash, H. Hake, U. Hammermüller, T. Hangen, K. Hecker, D. Herrmann, R. Holtorf, W. Hultzsch, HF Hüsgen, H. Johannsen, K. Karsten, K. Kirsten, B-M. Kniese, H. Krause, K-H. Krause, M. Krause, K-H. Laakmann, H-P. Loch, HH. Mahler, D. Manegold-Randel, MJ. Matting-Köhler, L. Maurer, T. Menke, S. Mohns-Petersen, C. Möllering, J. Monninger, B. Netzel, H. Outzen, H. Pankow-Culot, A. Paulus-Koschik, H. Preidel, C. Rüdiger, B. Protzmann, V. Reschke, L. Sander, S. Scharfe, E. Schmitz-Hauss, R. Schult, L. Seitz, C. Sievers, J. Stock, P. Soemantri, U. Sträubler, S. Strauch, K-J. Taube, D. Weyandt, C. Wittermann, R. Wollmerstädt, F. Zepp and B. zu Castell Rüdenhausen.
Author information
Authors and Affiliations
Corresponding author
Additional information
Source of financial support: GlaxoSmithKline Biologicals, Rixensart, Belgium.
Rights and permissions
About this article
Cite this article
Sänger, R., Behre, U., Krause, KH. et al. Booster vaccination and 1-year follow-up of 4–8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 166, 1229–1236 (2007). https://doi.org/10.1007/s00431-006-0403-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-006-0403-x